Please assess the completion status of the following clinical trial:

Trial Title: An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Sero-Positive Rheumatoid Arthritis Who Are Non-Responders or Intolerant to a Single TNF-Inhibitor (PORTSMAB)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, \>/= 18 years of age~* Rheumatoid arthritis positive for rheumatoid factor and/or anti-CCP~* Non-responder or intolerant to single TNF-inhibitor therapy~* Initiating treatment with MabThera/Rituxan~Exclusion Criteria:~* Contra-indications to MabThera/Rituxan therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rituximab (Type: None): Sero-positive \[Rheumatoid Factor (RF) and/or anti-Cyclic Citrullinated Peptide (CCP+)\] rheumatoid arthritis (RA) patients, who had initiated therapy with Rituximab (MabThera) following lack of response or intolerance to a single tumour necrosis factor (TNF)-inhibitor will be included in this arm

Based on this trial design, predict the completion outcome and termination type (if applicable).